Clinical features in 428 patients with DLBCL treated with R-CHOP chemotherapy, comparison of dual expresser MYC+BCL2+ vs non-MYC+BCL2+
| Clinical feature . | All (N = 428) . | MYC+BCL2+ (n = 127 [30%]) . | Non-MYC+BCL2+ (n = 301 [70%]) . | P . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. (%) . | Total . | Median (range) . | No. (%) . | Total . | Median (range) . | No. (%) . | Total . | Median (range) . | ||
| Follow-up, y | 6.8 (0.8-13.3) | 7.5 (1.9-12.9) | 6.9 (1.3-13.3) | — | ||||||
| Age, y | 65 (16-92) | 68 (16-87) | 62 (19-92) | |||||||
| >60 | 265 (62) | 92 (72) | 173 (57.5) | .004 | ||||||
| Male sex | 270 (63) | 74 (58) | 196 (65) | .18 | ||||||
| Stage 3 or 4 | 230 (54) | 77 (61) | 153 (51) | .06 | ||||||
| Elevated LDH* | 202 (51) | 399 | 70 (59) | 119 | 33 (12) | 280 | .098 | |||
| PS ≥2 | 140 (33) | 45 (35) | 95 (32) | .44 | ||||||
| Extranodal site | ||||||||||
| >1 | 74 (17) | 21 (16.5) | 53 (18) | .79 | ||||||
| Adrenal/kidney | 10 (2) | 5 (4) | 5 (2) | .15 | ||||||
| Testis | 10 (2) | 3 (2) | 7 (2) | .98 | ||||||
| CNS-IPI risk score† | 414 | 124 | 290 | |||||||
| Low (0 to 1) | 139 (34) | 35 (28) | 104 (36) | .10 | ||||||
| Intermediate (2 to 3) | 191 (46) | 55 (44) | 135 (46) | |||||||
| High (≥4) | 84 (20) | 34 (27) | 51 (18) | |||||||
| Hans COO‡ | 426 | 127 | 299 | |||||||
| Non-GCB | 185 (43) | 75 (59) | 110 (37) | <.0001 | ||||||
| GCB | 241 (57) | 52 (41) | 189 (63) | |||||||
| Lymph2Cx COO§ | 328 | 102 | 227 | |||||||
| ABC | 107 (33) | 57 (56) | 50 (22) | <.0001 | ||||||
| GCB | 182 (55) | 34 (33) | 148 (65) | |||||||
| Unclassified | 39 (12) | 11 (11) | 28 (12) | |||||||
| Clinical feature . | All (N = 428) . | MYC+BCL2+ (n = 127 [30%]) . | Non-MYC+BCL2+ (n = 301 [70%]) . | P . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. (%) . | Total . | Median (range) . | No. (%) . | Total . | Median (range) . | No. (%) . | Total . | Median (range) . | ||
| Follow-up, y | 6.8 (0.8-13.3) | 7.5 (1.9-12.9) | 6.9 (1.3-13.3) | — | ||||||
| Age, y | 65 (16-92) | 68 (16-87) | 62 (19-92) | |||||||
| >60 | 265 (62) | 92 (72) | 173 (57.5) | .004 | ||||||
| Male sex | 270 (63) | 74 (58) | 196 (65) | .18 | ||||||
| Stage 3 or 4 | 230 (54) | 77 (61) | 153 (51) | .06 | ||||||
| Elevated LDH* | 202 (51) | 399 | 70 (59) | 119 | 33 (12) | 280 | .098 | |||
| PS ≥2 | 140 (33) | 45 (35) | 95 (32) | .44 | ||||||
| Extranodal site | ||||||||||
| >1 | 74 (17) | 21 (16.5) | 53 (18) | .79 | ||||||
| Adrenal/kidney | 10 (2) | 5 (4) | 5 (2) | .15 | ||||||
| Testis | 10 (2) | 3 (2) | 7 (2) | .98 | ||||||
| CNS-IPI risk score† | 414 | 124 | 290 | |||||||
| Low (0 to 1) | 139 (34) | 35 (28) | 104 (36) | .10 | ||||||
| Intermediate (2 to 3) | 191 (46) | 55 (44) | 135 (46) | |||||||
| High (≥4) | 84 (20) | 34 (27) | 51 (18) | |||||||
| Hans COO‡ | 426 | 127 | 299 | |||||||
| Non-GCB | 185 (43) | 75 (59) | 110 (37) | <.0001 | ||||||
| GCB | 241 (57) | 52 (41) | 189 (63) | |||||||
| Lymph2Cx COO§ | 328 | 102 | 227 | |||||||
| ABC | 107 (33) | 57 (56) | 50 (22) | <.0001 | ||||||
| GCB | 182 (55) | 34 (33) | 148 (65) | |||||||
| Unclassified | 39 (12) | 11 (11) | 28 (12) | |||||||